Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–34 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tiotropium Inhalation Solution Clear all
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

NCT00776984
View directory record Official record
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
18
States / cities
Fountain Valley, California • Fresno, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Sep 25, 2026, 4:47 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT02275481
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Arformoterol tartrate inhalation solution, Tiotropium
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

NCT01634139
View directory record Official record
Conditions
Asthma
Interventions
Tiotropium low dose QD, Tiotropium high dose QD, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

NCT01172808
View directory record Official record
Conditions
Asthma
Interventions
Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

NCT02006732
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
olodaterol, tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
20
States / cities
Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113
View directory record Official record
Conditions
Asthma
Interventions
tiotropium-bromide, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431287
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Greer, California • Fort Collins, Colorado • Danbury, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

NCT01634152
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Tiotropium low dose mcg, Tiotropium high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One-Year Study

NCT00168831
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 25, 2026, 4:47 PM EDT